Playing with fire
Are we playing with fire – again?
A few years ago, Dr Philippe Armand at Dana Farber used this very colourful phrase accompanied by ‘rip roaring toxicities’ when describing autoimmune type reactions his institution had seen in patients with hematologic malignancies who had received prior allo SCT (see more here).
Now we’re starting to see more evidence emerge for improved activity with next generation bispecifics accompanied by lethalities.
Finding the balance between the two is proving to be something akin to a tightrope across the Niagara Falls without a safety net.
With so many runners and riders in the IO niche, it’s often hard to tell who will be the winner
Checkpoint blockade, CAR-T cells and fusion proteins haven’t been the only ones to struggle with this challenge, since bispecifics are also an immunotherapy approach capable of inducing some potent, if unwanted immune effects.
Here we look at the challenge in the bispecific arena with a focus on some recent events…
To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
